[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

51

1 I did not mention it, but lymphocytes
2 acquire the ability to produce IL-2 and Interferon
3 when stimulated in vitro with the immunogen, not
4 surprising in light of the proliferative responses.
5 The final slide, please, shows that there
6 is increased T-Cell cytotoxicity to the envelope
7 expressing autologous targets. I might mention that,
8 to a smaller degree, increased CTL, both CD4 and CD8
9 media in CTL, were seen also against gag-proteins,
10 paralleling the proliferative response data for P-24
11 that I presented.
12 Individuals -- essentially, all of them --
13 developed delayed type hypersensitivity to gp-160.
14 These individuals developed a quite striking delayed
15 type hypersensitivity to one, three or, occasionally,
16 ten micrograms that were required. That was seen in
17 only one individual -- or two individuals, rather, who
18 received the Hepatitis B vaccine, 32 micrograms, an
19 development, as you've seen, of antibodies to
20 additional HIV envelope determinants and increased
21 titers of antibodies, determinants against which
22 antibodies already exist.
NEAL R. GROSS
COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON, D.C. 20005 [phone]